El interés en corto de CalciMedica da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de CalciMedica. Los datos de interés en corto se actualizan cada dos semanas.

CalciMedica (NASDAQ:CALC) Bolsa, Informe de interés en corto

CalciMedica

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.

CalciMedica Inc

Calcitech Ltd

Calcol Inc

News

Management

Dana Appoints Current Director R. Bruce McDonald As Chairman And CEO

<p>Universal Health Realty Income Trust (NYSE:&nbsp;UHT) announced today that its Board of Trustees voted to increase the quarterly dividend by $.005 and pay a dividend of $.735 per share on December 31, 2024 to shareholders of record as of December 16, 2024.</p>


Dividends

Universal Health Realty Income Trust Announces Dividend Increase From $0.73 To $0.735 Per Share

<p><strong>Blue Bird</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:00 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Blue Bird missed estimated earnings by -16.0%, reporting an EPS of $0.77 versus an estimate of $0.92.</p>
<p>Revenue was up $47.25 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>In the previous quarter, the company beat on EPS by $0.4, resulting in a 0.0% increase change in the share price the following day.</p>
<p>Here's a look at Blue Bird's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.51</td>
<td>0.48</td>
<td>0.37</td>
<td>0.48</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.91</td>
<td>0.89</td>
<td>0.91</td>
<td>0.66</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>328.60M</td>
<td>298.41M</td>
<td>275.13M</td>
<td>290.11M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>333.37M</td>
<td>345.92M</td>
<td>317.66M</td>
<td>302.96M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Blue Bird <a href="https://www.benzinga.com/quote/BLBD/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

BLBD

Blue Bird Earnings Review: Q4 Summary

<p><strong>Woodward</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:00 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Woodward beat estimated earnings by 13.0%, reporting an EPS of $1.41 versus an estimate of $1.25.</p>
<p>Revenue was up $77.42 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>The company beat on EPS by $0.12 in the last quarter, resulting in a 17.0% drop share price change the following day.</p>
<p>Here's a look at Woodward's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.51</td>
<td>1.32</td>
<td>1.10</td>
<td>1.31</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.63</td>
<td>1.62</td>
<td>1.45</td>
<td>0.84</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>853.82M</td>
<td>807.00M</td>
<td>748.29M</td>
<td>765.35M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>847.69M</td>
<td>835.34M</td>
<td>786.73M</td>
<td>777.07M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Woodward management provided guidance for FY 2025, expecting earnings between $5.75 and $6.25 per share.</p>
<p>To track all earnings releases for Woodward <a href="https://www.benzinga.com/quote/WWD/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Woodward Earnings Report: Q4 Overview

<p><strong>Enanta Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) released its Q4 earnings on Monday, November 25, 2024 at 04:01 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Enanta Pharma beat estimated earnings by 4.0%, reporting an EPS of $-1.36 versus an estimate of $-1.41.</p>
<p>Revenue was down $4.33 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company beat on EPS by $0.38 in the previous quarter, leading to a 1.0% increase share price change the next day.</p>
<p>Here's a look at Enanta Pharma's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.45</td>
<td>-1.33</td>
<td>-1.19</td>
<td>-2</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.07</td>
<td>-1.47</td>
<td>-1.58</td>
<td>-1.33</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>17.18M</td>
<td>16.52M</td>
<td>21.28M</td>
<td>17.50M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>17.97M</td>
<td>17.05M</td>
<td>18.00M</td>
<td>18.93M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Enanta Pharma <a href="https://www.benzinga.com/quote/ENTA/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ENTA

Enanta Pharma: Q4 Earnings Insights

<p><strong>Central Garden &amp; Pet</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) announced its Q4 earnings on Monday, November 25, 2024 at 04:02 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Central Garden &amp; Pet beat estimated earnings by 10.0%, reporting an EPS of $-0.18 versus an estimate of $-0.2.</p>
<p>Revenue was down $80.66 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.11, leading to a 6.0% increase share price change the next day.</p>
<p>Here's a look at Central Garden &amp; Pet's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.21</td>
<td>0.80</td>
<td>-0.14</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.32</td>
<td>0.99</td>
<td>0.01</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.00B</td>
<td>887.42M</td>
<td>619.95M</td>
<td>735.32M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>996.35M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENT/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CENT

Insights into Central Garden & Pet Q4 Earnings

<p><strong>Pennant Park Investment</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:05 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Pennant Park Investment missed estimated earnings by 0.0%, reporting an EPS of $0.22 versus an estimate of $0.22.</p>
<p>Revenue was up $2.46 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.01, leading to a 1.0% increase share price change the next day.</p>
<p>Here's a look at Pennant Park Investment's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.23</td>
<td>0.24</td>
<td>0.23</td>
<td>0.22</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.24</td>
<td>0.22</td>
<td>0.24</td>
<td>0.24</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>36.66M</td>
<td>36.34M</td>
<td>32.74M</td>
<td>34.83M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>37.00M</td>
<td>35.98M</td>
<td>34.34M</td>
<td>34.04M</td>
</tr>
</tbody>
</table>
</p>
<p><strong> Listen to the earnings announcement yourself by <a href="">clicking here</a>. </strong></p>
<p>To track all earnings releases for Pennant Park Investment <a href="https://www.benzinga.com/quote/PNNT/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PNNT

Recap: Pennant Park Investment Q4 Earnings

<p>The earnings results for <strong>PennantPark Floating Rate</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFLT#NYSE">PFLT</a>) for Q4 were made public on Monday, November 25, 2024 at 04:05 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>PennantPark Floating Rate missed estimated earnings by 0.0%, reporting an EPS of $0.32 versus an estimate of $0.32.</p>
<p>Revenue was up $19.79 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>During the previous quarter, the company missed on EPS by $0.01, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at PennantPark Floating Rate's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.32</td>
<td>0.32</td>
<td>0.31</td>
<td>0.31</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.31</td>
<td>0.31</td>
<td>0.33</td>
<td>0.32</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>45.52M</td>
<td>39.45M</td>
<td>35.01M</td>
<td>34.59M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>48.51M</td>
<td>44.35M</td>
<td>37.97M</td>
<td>35.73M</td>
</tr>
</tbody>
</table>
</p>
<p><strong> Listen to the earnings announcement yourself by <a href="">clicking here</a>. </strong></p>
<p>To track all earnings releases for PennantPark Floating Rate <a href="https://www.benzinga.com/quote/PFLT/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PFLT

PennantPark Floating Rate Earnings Review: Q4 Summary

<p>The earnings results for <strong>StealthGas</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GASS#NASDAQ">GASS</a>) for Q3 were made public on Monday, November 25, 2024 at 09:10 AM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>StealthGas beat estimated earnings by 15.0%, reporting an EPS of $0.38 versus an estimate of $0.33.</p>
<p>Revenue was up $5.79 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>The company beat on EPS by $0.22 in the last quarter, resulting in a 2.0% drop share price change the following day.</p>
<p>Here's a look at StealthGas's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.53</td>
<td>0.24</td>
<td>0.30</td>
<td>0.15</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.75</td>
<td>0.53</td>
<td>0.29</td>
<td>0.16</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>39.20M</td>
<td>34.30M</td>
<td>33.90M</td>
<td>27.50M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>41.79M</td>
<td>41.56M</td>
<td>34.14M</td>
<td>34.65M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for StealthGas <a href="https://www.benzinga.com/quote/GASS/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


GASS

StealthGas Q3 Earnings Assessment

<p><strong>Fluence Energy</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:26 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Fluence Energy beat estimated earnings by 13.0%, reporting an EPS of $0.34 versus an estimate of $0.3.</p>
<p>Revenue was up $555.02 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company beat on EPS by $0.11 in the last quarter, resulting in a 15.0% increase share price change the following day.</p>
<p>Here's a look at Fluence Energy's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.11</td>
<td>-0.07</td>
<td>-0.13</td>
<td>-0.06</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0</td>
<td>-0.07</td>
<td>-0.14</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>455.51M</td>
<td>578.76M</td>
<td>407.61M</td>
<td>515.67M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>328.09M</td>
<td>623.14M</td>
<td>363.96M</td>
<td>672.98M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Fluence Energy <a href="https://www.benzinga.com/quote/FLNC/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FLNC

Fluence Energy Earnings Review: Q4 Summary

Asset Sales

Spruce Power Holding Corporation Class A Common Stock

SPRU

NJR Clean Energy Ventures Announces The Sale Of Its Residential Solar Portfolio To Spruce Power Holding For $132.5M

<p>Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.31 by 9.68 percent. This is a 1600 percent increase over earnings of $0.02 per share from the same period last year.  The company reported quarterly sales of $1.23 billion which missed the analyst consensus estimate of $1.30 billion by 5.61 percent.  This is a 82.47 percent increase over sales of $672.98 million the same period last year.</p>


Earnings Beats

Earnings Misses

Fluence Energy Q4 2024 GAAP EPS $0.34 Beats $0.31 Estimate, Sales $1.23B Miss $1.30B Estimate

WIIM

SANW

S&W Seed shares are trading higher after the company announced it has finalized the voluntary plan of administration  process for its subsidiary, S&W Seed Company Australia.

<p>BBB Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBBB#NYSE">TBBB</a>) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.03 by 233.33 percent.  The company reported quarterly sales of $784.20 million which beat the analyst consensus estimate of $776.51 million by 0.99 percent.</p>


TBBB

BBB Foods Q3 EPS $0.10 Beats $0.03 Estimate, Sales $784.20M Beat $776.51M Estimate

<p>As previously reported, S&amp;W Australia adopted a voluntary administration process on July 24, 2024, and on October 11, 2024 creditors of S&amp;W Australia approved a proposed Deed of Company Arrangement pursuant to which, among other things, 100% of the shares in S&amp;W Australia would be transferred to Avior Asset Management No. 3 Pty Ltd. The effective date of the DOCA is November 22, 2024.&nbsp;</p>


S&W Seed Finalizes Voluntary Plan Of Administration Process For Subsidiary S&W Australia; On November 22, S&W Entered Settlement Agreement In Exchange For Release From Intercompany Obligations Owed To S&W Australia

SMTC

Semtech shares are trading higher after the company reported better-than-expected Q3 adjusted EPS and sales, and provided Q4 EPS and revenue guidance above analyst estimates.

Semtech shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 guidance with its midpoint above estimates.

<p>Astronics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRO#NASDAQ">ATRO</a>) ("Astronics" or the "Company") today announced that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of convertible senior notes due 2030 (the "Notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Astronics also expects to grant to the initial purchasers of the Notes an option to purchase up to an additional $15 million aggregate principal amount of the Notes, for settlement within a 13-day period beginning on, and including, the first date on which the Notes are issued.</p>


Offerings

ATRO

Astronics Corporation Announces $150M Convertible Senior Notes Due 2030 Offering

LESL

Leslie's shares are trading lower after the company reported worse-than-expected Q4 adjusted EPS and sales.

<p>The Q4 earnings report for <strong>Leslies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) was released on Monday, November 25, 2024 at 04:05 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Leslies missed estimated earnings by -82.0%, reporting an EPS of $0.02 versus an estimate of $0.11.</p>
<p>Revenue was down $34.51 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous quarter, the company missed on EPS by $0.08, resulting in a 14.000000000000002% increase change in the share price the following day.</p>
<p>Here's a look at Leslies's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.42</td>
<td>-0.18</td>
<td>-0.21</td>
<td>0.18</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.34</td>
<td>-0.17</td>
<td>-0.20</td>
<td>0.14</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>615.41M</td>
<td>200.92M</td>
<td>169.61M</td>
<td>419.39M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>569.64M</td>
<td>188.66M</td>
<td>173.96M</td>
<td>432.37M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Leslies <a href="https://www.benzinga.com/quote/LESL/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Leslies Earnings Report: Q4 Overview

In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on CalciMedica (CALC – Research Report), with a price target o...

Oppenheimer Sticks to Their Buy Rating for CalciMedica (CALC)

An announcement from CalciMedica (CALC) is now available. CalciMedica, Inc. stockholders convened for the 2024 Annual Meeting, endorsing a key amen...

CalciMedica Shareholders Back Expansion and Elect Directors

CalciMedica (CALC) announced that it has commenced an underwritten public offering of its shares of common stock. All of the shares to be sold in t...

CalciMedica announces common stock offering, no amount given

CalciMedica announces proposed public offering of common stock

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on CalciMedica (CALC – Research Report) today and set a price target of $16.00. Jo...

CalciMedica's Auxora Shows Promise in Acute Pancreatitis: Analyst Recommends Buy

H.C. Wainwright analyst Joseph Pantginis lowered the firm's price target on CalciMedica (CALC) to $16 from $20 and keeps a Buy rating on the shares...

CalciMedica price target lowered to $16 from $20 at H.C. Wainwright

CalciMedica appoints Stephen Bardin as CFO

"These past few months have been very exciting for CalciMedica (CALC), punctuated by our announcement of the full data set and win ratio analysis f...

CalciMedica reports Q3 EPS (50c), consensus (50c)

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on CalciMedica (CALC – Research Report), retaining the price target of $16.00. ...

CalciMedica's Financial Strength and Clinical Advancements Lead to Buy Rating

CalciMedica GAAP EPS of -$0.50

CALC

Press Releases

CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference

CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Comments

CalciMedica

Interés en corto

CalciMedica (NASDAQ:CALC) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL